

S/N 10/594,100

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Geng et al.	Examiner:	Maier, Leigh C.
Serial No.:	10/594100	Group Art Unit:	1623
Filed:	June 29, 2007	Docket No.:	09548.1045USWO
Title:	ALGIN OLIGOSACCHARIDES AND THE DERIVATIVES THEREOF AS WELL AS THE MANUFACTURE AND THE USE OF THE SAME		

DECLARATION UNDER 37 CFR §1.132

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

I, Meiyu Geng, Ph.D, hereby declare as follows:

1. I obtained my bachelor degree in Medicine in 1986 and master degree in pharmacology in 1989 from Shandong Medical University (Now Shandong University). I got my Ph.D in Pharmacy from Tokyo University in 1996.

2. I have worked in Marine Drug and Food Institute of Ocean University of China since 1989. I have started from the discovery to the development of carbohydrate-based drugs covering a descriptive phenomenon into molecular understanding in Alzheimer's treatment to cancer therapy in the past decade. Major interests are mainly focused on the research and development of targeted molecular agents in particular A β -targeting inhibitors, and deciphering of the possible molecular mechanisms in signal transduction. Currently, I am also focusing on characterizing genomics-based new targets and investigating the impact of biomarkers in AD progression and therapy response as well.

Based on the established glyco-microarray technique for high-throughput and micro-scale screening of biologically active marine-derived oligosaccharides, I have found a series of potential oligosaccharide-based drug candidates, including anti-AD drug candidate oligomannurinate and heparanase inhibitor JG3. During the past decades, more than 60 papers have been published in peer-reviewed journals and over 10 patents have been filed and 5 patents have been authorized.

I found that oligomannurinate, a novel marine-derived oligosaccharide, inhibits the entire fibril-forming process by stabilizing A β in an α -helical state, by driving disassembled fibrils into non-toxic conformers both in vitro and in a transgenic mouse model. Notably, this efficacy occurs via the binding capacity of oligomannurinate for N-terminus and β -hairpin species at different stages by simultaneously targeting SNK and HHQK domains on A β peptide. These features, together with good oral bioavailability, blood-brain barrier accessibility, and favorable safety and tolerability in newly completed

Phase I clinical trials, make oligomannurinate both a prophylactic and therapeutic drug candidate for AD therapy. Now, oligomannurinate is under phase II clinical trial in China.

Inhibitors of tumor angiogenesis and metastasis are increasingly emerging as promising agents for cancer therapy. Recently, heparanase inhibitors have offered a new avenue for such work because heparanase is thought to be critically involved in the metastatic and angiogenic potentials of tumor cells. I found that oligomannurinate sulfate (JG3), a novel marine-derived oligosaccharide, acts as a heparanase inhibitor to inhibit tumor angiogenesis and metastasis both *in vitro* and *in vivo* by combating heparanase activity via binding to the KKDC and QPLK domains of the heparanase molecule, making JG3 a promising candidate agent for cancer therapy.

In addition, I have also discovered another sulfated polymannuroguluronate (SPMG), extracted from brown algae followed by chemical modification, inhibited HIV replication via its binding to the V3 region of the capsid glycoprotein molecule of the virus, gp120, therefore interrupting the binding of V3 region to CXCR4 and CCR5 (both are the co-receptors to CD4 molecule) and further preventing the entry of HIV into the host cells.

3. I am one of the inventors for the invention described in US Patent Application No. 10/594100 and am familiar with the subject matter thereof.

Alzheimer's disease (AD) is a devastating neurological disorder that affects more than 37 million people worldwide. The economic burden of AD is massive. Currently approved drugs for AD ameliorate symptoms for a short time by boosting levels of neurotransmitters, but do not alter the general progression or outcome of the disease.

Intense efforts have been devoted to finding disease-modifying therapies that target the underlying AD pathogenic molecules. Of these, β -amyloid peptide ($A\beta$), a 39-43 residue cleavage product of amyloid precursor protein, is the main component of senile plaques of AD, constitutes the focus of current interest.

Since amyloid fibril formation is a multi-stage process involving different $A\beta$ species at different stages, an exciting current anti-AD strategy is to challenge mechanism-based multi-targeting agents. To this end, inhibitors should be broadly active across multiple stages of fibrillation. Such ideal agents are thus anticipated to stabilize $A\beta$ in monomeric state that are unable to further assemble, favor the disassembly of high molecular-weight oligomers and fibrillar deposits in non-toxic conformers, and encourage its clearance through normal pathways by maintaining the $A\beta$ in a monomer state.

With the availability of various synthetic $A\beta$ species and a marine-derived carbohydrate library in our lab, a comprehensive screening program was undertaken. Oligomannurinate, an acidic oligosaccharide obtained from degradation and subsequent chemical modification, stood out as a full inhibitor of β -amyloid cascades by binding to Ser26-to-Lys28 (SNK) residues and simultaneously to the HHQK motif in $A\beta$ peptide. oligomannurinate arrests fibril formation by stabilizing $A\beta$ in an α -helix, and destabilizes fibrils into non-toxic conformers both *in vitro* and in a transgenic mouse model. The applied patent with No. 10/594100 generated from this product oligomannurinate.

3. The following supplementary experiments were conducted under my direction.

Supplementary Experimental Data:


To observe the binding affinity of each oligomer with A β and the inhibition of each oligomer on neurotoxicity of A β , SPR technique (BIAcore X, Uppsala, Sweden) is used to characterize the interaction of each oligomer and A β , according to the disclosure in [0096] of the US 10/594,100.

The results are shown in Table 1, indicating that all the tested oligomer have strong binding affinity with A β_{1-40} .

Table 1. Binding affinity of each oligomers with aged A β_{1-40} detected by SPR

Mannuronic acid oligosaccharide	K _D (M)
2-mer	1.05E-06
3-mer	6.35E-07
4-mer	1.65E-08
5-mer	1.23E-08
6-mer	1.33E-08
7-mer	1.56E-08
8-mer	1.67E-08
9-mer	1.29E-08
10-mer	1.42E-08

An in vitro cell cultivation is used to observe the influence of each oligomer on the damage of neuron SY-SH5Y caused by aged A β_{1-40} . The results (Figure 1) shows that all the tested oligomers may apparently inhibit neuron damage caused by aged A β_{1-40} .



I declare under the penalty of perjury of the laws of the United States of America
that the foregoing is true and correct to the best of my information and belief.

Signed by *Meiyu Geng*

Print name *Meiyu Geng*

Date: *2010.7.5*

Place *Qingdao*